Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00191334 | Gemcitabine in Ovarian Cancer | completed | Phase 2 | 50 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 27, 2009 | clinicaltrials |
| NCT00113789 | Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer | completed | Phase 2 | 21 | AmgenINDUSTRY | 0 | Feb 13, 2009 | clinicaltrials |
| NCT00400348 |
| Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer |
| completed |
| Phase 2 |
| 18 |
| CASI pharmaceuticals, Inc.INDUSTRY |
| 1 |
| Nov 25, 2008 |
| clinicaltrials |
| NCT00772798 | A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer | unknown | Phase 2 | 70 | Herlev HospitalOTHER | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00075543 | Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | unknown | Phase 1 / Phase 2 | — | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 24, 2008 | clinicaltrials |
| NCT00157560 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma | completed | Phase 2 | 83 | Massachusetts General HospitalOTHER | 1 | Jan 3, 2008 | clinicaltrials |
| NCT00086632 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment | terminated | Phase 2 | 40 | Unither PharmaceuticalsINDUSTRY | 0 | Dec 18, 2007 | clinicaltrials |
| NCT00189579 | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer | terminated | Phase 2 | 45 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00490711 | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 7 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00103545 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | completed | Phase 1 / Phase 2 | 36 | AGO Study GroupOTHER | 1 | Oct 2, 2006 | clinicaltrials |
| NCT00055432 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | terminated | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Sep 15, 2006 | clinicaltrials |
| NCT00194935 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | terminated | Phase 2 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00070967 | Acupuncture to Improve Quality of Life in Patients With Advanced Cancer | completed | Phase 2 | 40 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
| NCT00231075 | Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV | completed | Phase 2 | 75 | ARCAGY/ GINECO GROUPOTHER | 1 | Nov 3, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Mar 27, 2009source: clinicaltrials